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A B S T R A C T
Background: People who inject drugs often get bacterial infections. Few longitudinal studies have reported the
incidence and treatment costs of these infections.
Methods: For a cohort of 2335 people who inject heroin entering treatment for drug dependence between 2006
and 2017 in London, England, we reported the rates of hospitalisation or death with primary causes of cutaneous
abscess, cellulitis, phlebitis, septicaemia, osteomyelitis, septic arthritis, endocarditis, or necrotising fasciitis. We
compared these rates to the general population. We also used NHS reference costs to calculate the cost of
admissions.
Results: During a median of 8.0 years of follow-up, 24 % of patients (570/2335) had a severe bacterial infection,
most commonly presenting with cutaneous abscesses or cellulitis. Bacterial infections accounted for 13 % of all
hospital admissions. The rate was 73 per 1000 person-years (95 % CI 69–77); 50 times the general population,
and the rate remained high throughout follow-up. The rate of severe bacterial infections for women was 1.50 (95
% CI 1.32–1.69) times the rate for men. The mean cost per admission was £4980, and we estimate that the
annual cost of hospital treatment for people who inject heroin in London is £4.5 million.
Conclusions: People who inject heroin have extreme and long-term risk of severe bacterial infections.
1. Introduction
Bacterial infections are common among people who inject illicit
drugs. Cutaneous abscesses, cellulitis and other localised infections are
some of the most frequent reasons for medical care in this population.
These infection can be serious, sometimes requiring hospital treatment
or leading to complications such as invasive infections and amputa-
tions. Cross-sectional studies show that between 7 % and 37 % of
people who inject drugs report a soft tissue infection in the last 6–12
months, and lifetime prevalence may be as high as 70 % (Coull et al.,
2014; Larney et al., 2017). Invasive bacterial infections at sites such as
the bones, joints, heart, and blood, are also more common among
people who inject drugs than the general population, and have a high
mortality risk (Frontera and Gradon, 2000; Peterson et al., 2014). Time-
series data suggest that the number of hospital admissions for injecting-
related bacterial infections is increasing in the US and the UK
(Ciccarone et al., 2016; Lewer et al., 2017).
Several elements of a causal pathway have been established. These
include colonisation of the skin; transferring bacteria onto drugs when
they are transported (for example in the mouth); frequent breaking of
the skin when injecting (and sometimes through other injuries) (Phillips
et al., 2017); and longer-term damage to the skin, soft tissue and veins
with acids and particulate matter in drug preparations, which increases
vulnerability to infection (Harris et al., 2019; Hope et al., 2008; Murphy
et al., 2001; Packer et al., 2019). Clusters of unusual infections such as
anthrax and botulism have been observed among people who use illicit
drugs (Trayner et al., 2018), but there is likely to be many more in-
fections and deaths caused by common species such as streptococci and
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staphylococci from the patient’s own skin or mouth (Gordon, 2005).
Cross-sectional studies have identified that women, people who inject
subcutaneously, homeless people, and those who inject stimulants have
raised prevalence (Hope et al., 2008, 2016; Murphy et al., 2001). These
groups may inject more frequently or have poorer access to sterile and
sharp injecting equipment.
However, relatively few studies have reported the incidence and
costs of bacterial infections among people who inject drugs, particularly
in comparison to the large number of studies of blood-borne viral in-
fections in this population (Degenhardt et al., 2016). This may be be-
cause most existing studies into bacterial infection use cross-sectional
self-report data. In contrast to this, we used longitudinal electronic
health record data to estimate the rate and treatment costs for severe
bacterial infections in a cohort of people who inject heroin in South
London, England.
2. Materials and methods
2.1. Data source
We used data from the Clinical Records Interactive Search (CRIS)
resource at the South London and Maudsley NHS Foundation Trust
Biomedical Research Centre. This is a research repository of anon-
ymised data derived from the electronic health record system of a
mental healthcare provider in South London, England (Perera et al.,
2016). The study population was 2335 patients aged 18–64 entering
community-based substance use treatment between 1 January 2006
and 31 March 2017, with reported use of heroin and drug injection.
Patients were linked using NHS number, date of birth, sex and postcode
to inpatient hospital admissions data from the national Hospital Epi-
sode Statistics for England database, and to mortality data from the UK
Office for National Statistics. Linkage was conducted by NHS Digital, a
public sector statistical agency. The end of follow-up was the partici-
pant’s 65th birthday, death, or 31 March 2017. Some patients have long
periods of engagement with the drug treatment service, while other
only attend one appointment, but data linkage was available for all
patients regardless of their engagement with the service. We treated
admissions within two days of discharge after a previous admission as a
single admission. We also accessed hospital admission data for all re-
sidents in the healthcare provider’s catchment area of the London
Boroughs of Croydon, Lambeth, Lewisham and Southwark (the ‘com-
parison group’).
2.2. Outcome measures
We defined severe bacterial infections as hospital admission with a
primary cause of cutaneous abscess (ICD-10 code L02), cellulitis (L03),
phlebitis or thrombophlebitis (I80), sepsis or septicaemia (A40, A41),
endocarditis (I30.1, I39, I33.0, 140.0, I41.0), septic arthritis or osteo-
myelitis (M86, M00, M463, M46.5), and necrotising fasciitis (M72.6).
We also counted all-cause hospital admissions.
2.3. Participant characteristics
Data were derived from routinely collected information. Drugs used
by patients and ‘route of administration’ (i.e. whether the patient re-
ports injecting) were from the treatment service’s National Drug
Treatment Monitoring System (NDTMS) data set. This is a standardised
patient assessment conducted periodically by drug treatment services in
England (Marsden et al., 2009; Public Health England, 2018a). We
identified that patients injected heroin if this was recorded on any
NDTMS record during follow-up. In most of these cases, heroin injec-
tion was recorded on the earliest record, but we also included patients
where it was recorded later, since some patients do not initially disclose
injection. Date of birth and sex were taken from the healthcare provi-
der’s central patient database. For descriptive purposes, we reported:
(a) drugs other than heroin were listed for at least 10 % of participants,
(b) whether homelessness or unstable housing was listed in patient
databases, and (c) whether serious mental illness, defined as a diagnosis
or bipolar disorder or schizophrenia, was listed in patient databases.
2.4. Statistical analysis
To calculate an expected number of admissions, we first calculated
admission rates in the comparison group from 2006 to 2016 (as the
closest available match to the study cohort) by age group, sex, and type
of infection. The denominators were the sum of mid-year population
estimates (Office for National Statistics, 2017) in the service provider’s
catchment boroughs, and the numerators were the numbers of hospital
admissions. We applied these rates to the time-at-risk within each age
and sex group in the study cohort, accounting for patients ageing during
follow-up and not counting time while patients were admitted to hos-
pital. The standardised admission ratio (SAR) was the observed ad-
missions divided by the expected admissions (i.e. indirect standardi-
sation). We also stratified these results by sex.
We estimated the cost of each hospital admission using the NHS
2014/15 national reference costs (Department of Health and Social
Care, 2015), in which hospitals report spend according to diagnoses,
clinical procedures and the duration of admissions. The cost of each
admission is calculated using a combination of the diagnosis codes,
procedure codes, and length of admission. To contextualise these costs,
we estimated the annual cost of hospital treatment for bacterial infec-
tions among all people who inject drugs in London, by applying the
admission rates in our cohort to an existing capture-recapture popula-
tion estimate of 11,351 people who inject drugs in London in 2011/12
(Hay et al., 2014), and using the mean cost of treatment for each di-
agnosis from our cohort. We used a Monte-Carlo method to estimate
statistical uncertainty around this estimate, with details of this method
provided in Supplementary Information.
To compare the duration of hospital admission for patients who
inject drugs and the general population, we drew a random sample of
admissions from the comparison group, stratified by age group, sex,
primary diagnosis, and year, at a ratio of 1:1.
Analysis was conducted using R version 3.5.3 (R Core Team, 2019).
3. Results
The cohort included 2335 patients with a total follow-up time of
16,242 years (median 8.0, range 0–11.2). The mean age at baseline was
36.3 years (sd 8.4) and 1727 (74 %) were male, which is similar to the
profile of people entering opioid treatment nationally (Public Health
England and Department of Health, 2017) (Table 1). 352 patients died
(15 %) during follow-up, of whom<10 had an underlying cause of a
bacterial infection.
Of an initial cohort of 2469 patients, 134 (5 %) were not linked to
NHS hospital data and were excluded from analysis. Excluded patients
did not differ in terms of sex (p = 0.49), but were slightly younger at
baseline (mean age 34.2 vs. 36.4 years; p = 0.005).
3.1. Hospitalisation
Patients were hospitalised 9315 times, of which 1180 (13 %) were
primarily caused by a bacterial infection. The incidence density was 73
hospitalisations per 1000 person-years (95 % CI 69–77). The rate of
bacterial infections was high throughout follow-up, with no evidence of
a change in incidence over time for either men or women (Fig. 1).
Compared to the general population, the study cohort was 50.0 (95
% CI 47.2−52.9) times more likely to be admitted to hospital for
treatment of a bacterial infection. Hospitalisation rates were sub-
stantially raised for each type of bacterial infection (Table 2). The rate
of all-cause admission was also raised, but much less so, at 3.7 times the
general population.
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The rate of hospitalisation among women was 1.50 (95 % CI
1.32–1.69) that of men, with similar or higher rates across diagnoses
(Fig. 2). Although women also had a higher rate of all-cause hospital
admission than men, this was in proportion to differences between
women and men in the general population. All-cause SARs for men and
women were therefore similar, at 3.7 and 4.0 respectively. In contrast,
women who inject heroin had higher rates of admission for bacterial
infections than men, and the differences were disproportionate to un-
derlying differences between men and women in the general popula-
tion. The SARs for bacterial infections were therefore higher for women
than for men (see Supplementary Information).
Compared to hospital inpatients from the general population with
the same age, sex, primary cause of hospital admission and year of
admission, patients who inject heroin had a longer duration of
admission (mean 7.4 days) and were more likely to self-discharge (13 %
vs. 1 %). Comparisons of the duration, admission method and discharge
methods for people who inject heroin and the general population are
provided in Supplementary Information.
3.2. Cost of treatment
The mean cost per admission was £4980 (sd. £12,431), with higher
costs for invasive infections. The cost per admission was heavily right-
skewed (common in healthcare cost data) and means were higher than
medians. Modelling suggested 869 admissions for treatment of bacterial
infections per year among 11,351 people who inject drugs in London,
with a total cost of £4.5 million (95 % CI £3.7-£5.4 million), based on
2014/15 prices.
4. Discussion
In this cohort of people who inject heroin in South London, bacterial
infections were a major cause of morbidity but not mortality. Our re-
sults show a 50-fold increased risk of severe bacterial infections when
compared to the general population, with high risk persisting for sev-
eral years after starting treatment.
Hospital treatment of bacterial infections in people who inject drugs
can be complex and expensive. Clinicians sometimes retain these pa-
tients in hospital for longer to ensure antibiotic courses are completed.
Patients may leave hospital against medical advice if opiate substitution
is unavailable (Summers et al., 2018) and often have poor continuing
care, leading to readmission and antimicrobial-resistant infections. In
our sample, 13 % of admissions ended in discharge against medical
advice, compared to 1 % of admissions in the comparison group. Our
results suggest that the cost of hospitalisations for these conditions is
£4.5 million per year in London (2014/15 prices), which is substantial
considering that the total expenditure on drug misuse treatment in
London in 2017/18 was £64 million (Ministry of Housing, Communities
and Local Government, 2018).A previous study estimated costs of
hospital treatment for bacterial infection among people who inject
drugs in England using the mean cost of treatment in the general
Table 1
Cohort characteristics at baseline.
Variable Level Number (%)
Age at index 18−24 217 (9)
25−34 842 (36)
35−44 921 (39)
45−54 314 (13)
55−64 41 (2)
Mean (sd) 36.3 (8.4)
Age during follow-up Mean (sd) 39.9 (8.4)
Sex Male 1727 (74)
Female 608 (26)
Ethnicity White 2065 (88)
Black 119 (5)
Mixed 66 (3)
Asian 28 (1)
Other 57 (2)
Other drugs Crack cocaine 1950 (84)
Alcohol 1198 (51)
Cannabis 513 (22)
Benzodiazepines 386 (17)
Unstable housing 1410 (60)
Severe mental health problems 366 (16)
Total 2335 (100)
Fig. 1. Rate of hospital admission for severe bacterial infection in a cohort of 2335 people who inject heroin in South London, England, by time after first treatment
episode (error bars show 95% confidence intervals).
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population, at £944 to £1566 per admission (2004/05 prices) (Hope
et al., 2008). Our data show substantially higher costs among people
who inject drugs, at £4980 per admission (2014/15 prices), which is
similar to a study of 128 episodes of bacterial infection in people who
inject drugs at one London hospital (Marks et al., 2013).
The incidence rate of severe bacterial infections (73/1000 person-
years) was higher than rates observed in cohorts of people who inject
opiates in Sweden (24/1000) and Canada (61/1000) (Dahlman et al.,
2018; Lloyd-Smith et al., 2010) and lower than a rate observed in
Switzerland (86/1000) (Bassetti et al., 2002). The variation is likely due
to differing demographics, injecting behaviours, types of heroin, local
services, and the period when the study was conducted. The higher risk
associated with female sex is consistent across these studies.
Many studies have shown that women form a minority among
people who inject drugs, with higher risk of acquiring infections. As
well as higher risk of bacterial infections, some studies have shown than
women who inject drugs have higher risk of acquiring blood-borne viral
infections than men, with the difference at least partly due to injecting-
related risks such as sharing syringes, injection by partners, and
younger age at first injection (Doherty et al., 2000; Tracy et al., 2014).
Women who inject drugs may face greater self-stigma and social stigma
relating to drug injection and injection-related injuries (Iversen et al.,
2015), and may therefore avoid health services. Policy recommenda-
tions to reduce HIV risk among women who inject drugs have argued
that the most successful interventions focus on contextual factors such
as women’s intimate relationships, housing, employment, and childcare
arrangements, rather injecting behaviours (Pinkham et al., 2012), and
this may also be true for bacterial infections.
A large proportion of our sample (60 %) had experienced home-
lessness or housing problems. The association between housing pro-
blems and bacterial infections among people who inject drugs has been
shown in previous studies (Dahlman et al., 2018; Hope et al., 2008).
Sleeping in homeless shelters and other temporary accommodation may
be associated with increased bacterial colonisation (Leibler et al.,
2019). Homeless people are also more likely to inject in public places,
which is associated with rushing the procedure, not cleaning skin be-
fore injecting, a lack of clean water for preparing drug solutions, and
not having a clean surface to assemble the drugs (Small et al., 2007),
which increase the risk of infection. Interventions to improve housing in
this population may reduce the risk of bacterial infections, as well as
improving many other health and social outcomes. Among people using
accommodation with shared bathroom facilities, improved shower hy-
giene may decrease the risk of colonisation (Leibler et al., 2019).
Qualitative research has found multiple barriers to healthcare
among people who inject drugs. People may delay treatment due to
normalisation of pain, fear of stigma in services, and concern about
inadequate opioid substitution and pain control when admitted to
hospital (Neale et al., 2007; Summers et al., 2018). Hospitals sometimes
Table 2
Hospital admissions and costs of treatment for severe bacterial infections in a cohort of 2335 people who inject heroin in South London, England, with 16,434 years of
follow-up.
Primary diagnosis Observed admissions Expected admissions SAR
(95 % CI)
Mean cost, £ (sd) Median cost, £
(IQR)
Abscess 487 9.3 52.4 (47.8−57.2) 4307 (3035) 3898 (2,660−5,296)
Cellulitis 282 7.8 36.0 (31.9−40.4) 3579 (2503) 2731 (1,880−4,432)
Phlebitis and thrombophlebitis 233 2.0 115.2 (100.9−131.0) 3261 (2969) 2277 (1,772−4,136)
Septicaemia and bacteraemia 56 2.3 24.3 (18.3−31.5) 8687 (5060) 9250 (5,221−9,763)
Osteomyelitis and septic arthritis 42 0.2 174.4 (125.7−235.8) 14,134 (52,843) 5694 (3,980−7,129)
Endocarditis 82 1.9 43.7 (34.8−54.3) 12,963 (7765) 11,951 (6,893−15,197)
Necrotising Fasciitis 9 < 0.1 599.4 (274.1−1,137.9) 10,815 (7159) 11,926 (4,274−14,839)
All bacterial infections* 1180 23.6 50.0 (47.2−52.9) 4980 (12,431) 3022 (2,148−5,296)
All-cause 9274 2467.5 3.8 (3.7−3.8) ** **
SAR = Standardised admission ratio.
* The total number of bacterial infections is less than the sum of each individual diagnosis because some admissions have two primary diagnoses (resulting from
the process of merging hospital admissions that were within two days of each other).
** We did not calculate the cost of admissions with primary diagnosis unrelated to bacterial infection.
Fig. 2. Rate of hospital admission for severe bacterial infection in a cohort of 2335 people who inject heroin, by primary diagnosis. (error bars show 95% confidence
intervals).
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employ drug and alcohol liaison workers a to improve accessibility for
people who use drugs, and this may lead to more effective treatment
(Reeve et al., 2016). Early treatment may also be encouraged by spe-
cialist community clinics that provide antibiotics and wound care.
These services are sometimes commissioned as part of community drug
services, but may have become less available in England as funding for
addictions services has reduced (Advisory Council on the Misuse of
Drugs, 2017).
In addition to interventions focusing on gender, housing, and health
service accessibility, there are several effective interventions that re-
duce injecting-related risk. These include interventions that reduce the
need for injecting, such as opiate substitution; and interventions that
improve injecting safety and hygiene, such as safe injecting facilities
and provision of sterile injecting equipment (Dunleavy et al., 2017).
We observed continued high risk of severe bacterial ten years after
initiation of treatment. This reflects the long-term nature of heroin
dependence and highlights the need for continued health assessments
and inspection of injecting sites.
4.1. Strengths and limitation
Recruiting and retaining people who use drugs in traditional cohort
studies can be challenging, and many studies are small and suffer from
loss-to-follow-up. Strengths of our study include the large sample size,
long follow-up, and complete data on hospitalisations and deaths. The
linked hospital records were available from all NHS hospitals in
England (rather than only local hospitals), which is important because
people who use drugs are mobile and may use health services in other
parts of the country. In our study, 55 % of admissions occurred outside
of the four local London boroughs.
Our sample is drawn from a community drug treatment service, and
therefore excludes people who have never sought treatment. In
England, an estimated three-quarters of people who use illicit opiates
have had at least one episode of treatment and half are currently en-
gaged with treatment (Public Health England, 2018b). Those who have
never engaged with treatment may include both higher risk patients
who are not accessing harm reduction services, and lower risk patients
who have lower need for services. Given the high proportion of the
population who have used drug treatment services, our results are likely
to be a reasonable estimate of the rate of infection among people who
inject heroin in London.
We focused on severe infections that require inpatient treatment.
Community surveys suggest that soft tissue infections are very common
in people who inject drugs (Larney et al., 2017), and many self-treat
(Monteiro et al., 2020) or wait for symptoms to resolve. Additionally,
some patients will have sought treatment for less severe infections from
general practitioners, but we did not have access to primary care data
for this study. Consequently, this study only captures the most severe
infections and provides a lower bound for healthcare utilisation.
Although our data included potential risk factors for bacterial in-
fections, such as housing status and mental health problems, we did not
seek to analyse their association with the risk of bacterial infections.
Previous studies have reported risk factors for bacterial infections in
this population, and our data lacked detailed information relating to
injecting risk, such as duration and frequency of injecting. This study
highlights that cohorts based on electronic health records such as ours
have strengths when reporting of incidence and costs, but may be
limited when analysing risk factors or ‘risk environments’, which re-
quires a detailed understanding of participants’ context.
5. Conclusions
People who inject heroin have extreme and long-term risk of severe
bacterial infections. Women are at higher risk than men.
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